Tissium

TISSIUM develops a platform of biomorphic programmable polymers for tissue reconstruction, together with activation technologies and delivery devices. Its COAPTIUM® CONNECT system is described as the first and only FDA-authorized system for atraumatic sutureless nerve coaptation and is commercially available in the United States. The pipeline covers peripheral nerve, cardiovascular and gastrointestinal areas, and includes the ECLIPSIUM hernia program.

The company designs solutions for open surgery and minimally invasive procedures. Its customers are surgeons and medtech companies, the latter through co-development partnerships. The website does not describe its pricing or sales model in detail.

TISSIUM was founded in 2013 on polymer research from the MIT labs of Bob Langer and Jeff Karp. The site lists a manufacturing site in Roncq, France, which is ISO certified, and job postings in Boston. The site reports 143 patents granted and 27 patent families filed. Open roles at the time of capture span product development, quality, clinical affairs, marketing, chemistry-manufacturing-controls and HR.

Product: COAPTIUM® CONNECT, a sutureless nerve coaptation system, and a platform of biomorphic programmable polymers for tissue reconstruction.